Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy
Maureen L Drakes, Patrick J Stiff Department of Medicine, Division of Hematology and Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA Abstract: Despite improved methods of cancer detection and disease management over the last few decades, cancer remains a major publ...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-12-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/harnessing-immunosurveillance-current-developments-and-future-directio-peer-reviewed-article-ITT |
| _version_ | 1811205633307836416 |
|---|---|
| author | Drakes ML Stiff PJ |
| author_facet | Drakes ML Stiff PJ |
| author_sort | Drakes ML |
| collection | DOAJ |
| description | Maureen L Drakes, Patrick J Stiff Department of Medicine, Division of Hematology and Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA Abstract: Despite improved methods of cancer detection and disease management over the last few decades, cancer remains a major public health problem in many societies. Conventional therapies, such as chemotherapy, radiation, and surgery, are not usually sufficient to prevent disease recurrence. Therefore, efforts have been focused on developing novel therapies to manage metastatic disease and to prolong disease-free and overall survival, by modulating the immune system to alleviate immunosuppression, and to enhance antitumor immunity. This review discusses protumor mechanisms in patients that circumvent host immunosurveillance, and addresses current immunotherapy modalities designed to target these mechanisms. Given the complexity of cancer immunosuppressive mechanisms, we propose that identification of novel disease biomarkers will drive the development of more targeted immunotherapy. Finally, administration of different classes of immunotherapy in combination regimens, will be the ultimate route to impact low survival rates in advanced cancer patients. Keywords: cancer, immunotherapy, immunosurveillance, immunosuppression, dendritic cells, T-cells |
| first_indexed | 2024-04-12T03:35:28Z |
| format | Article |
| id | doaj.art-631aa71d79f2478f8bd159bc87a8d26e |
| institution | Directory Open Access Journal |
| issn | 2253-1556 |
| language | English |
| last_indexed | 2024-04-12T03:35:28Z |
| publishDate | 2014-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj.art-631aa71d79f2478f8bd159bc87a8d26e2022-12-22T03:49:26ZengDove Medical PressImmunoTargets and Therapy2253-15562014-12-012014Issue 115116519423Harnessing immunosurveillance: current developments and future directions in cancer immunotherapyDrakes MLStiff PJMaureen L Drakes, Patrick J Stiff Department of Medicine, Division of Hematology and Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA Abstract: Despite improved methods of cancer detection and disease management over the last few decades, cancer remains a major public health problem in many societies. Conventional therapies, such as chemotherapy, radiation, and surgery, are not usually sufficient to prevent disease recurrence. Therefore, efforts have been focused on developing novel therapies to manage metastatic disease and to prolong disease-free and overall survival, by modulating the immune system to alleviate immunosuppression, and to enhance antitumor immunity. This review discusses protumor mechanisms in patients that circumvent host immunosurveillance, and addresses current immunotherapy modalities designed to target these mechanisms. Given the complexity of cancer immunosuppressive mechanisms, we propose that identification of novel disease biomarkers will drive the development of more targeted immunotherapy. Finally, administration of different classes of immunotherapy in combination regimens, will be the ultimate route to impact low survival rates in advanced cancer patients. Keywords: cancer, immunotherapy, immunosurveillance, immunosuppression, dendritic cells, T-cellshttps://www.dovepress.com/harnessing-immunosurveillance-current-developments-and-future-directio-peer-reviewed-article-ITTcancerimmunotherapyimmunosurveillanceimmune suppressiondendritic cellsT cells |
| spellingShingle | Drakes ML Stiff PJ Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy ImmunoTargets and Therapy cancer immunotherapy immunosurveillance immune suppression dendritic cells T cells |
| title | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| title_full | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| title_fullStr | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| title_full_unstemmed | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| title_short | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| title_sort | harnessing immunosurveillance current developments and future directions in cancer immunotherapy |
| topic | cancer immunotherapy immunosurveillance immune suppression dendritic cells T cells |
| url | https://www.dovepress.com/harnessing-immunosurveillance-current-developments-and-future-directio-peer-reviewed-article-ITT |
| work_keys_str_mv | AT drakesml harnessingimmunosurveillancecurrentdevelopmentsandfuturedirectionsincancerimmunotherapy AT stiffpj harnessingimmunosurveillancecurrentdevelopmentsandfuturedirectionsincancerimmunotherapy |